"Biological Products" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
| Descriptor ID |
D001688
|
| MeSH Number(s) |
D20.215
|
| Concept/Terms |
Biological Products- Biological Products
- Biologic Products
- Products, Biologic
- Biologics
- Products, Biological
|
Below are MeSH descriptors whose meaning is more general than "Biological Products".
Below are MeSH descriptors whose meaning is more specific than "Biological Products".
This graph shows the total number of publications written about "Biological Products" by people in this website by year, and whether "Biological Products" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 5 | 0 | 5 |
| 2009 | 1 | 0 | 1 |
| 2010 | 4 | 1 | 5 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 1 | 4 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 0 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 2 | 4 |
| 2018 | 11 | 3 | 14 |
| 2019 | 8 | 5 | 13 |
| 2020 | 7 | 3 | 10 |
| 2021 | 12 | 2 | 14 |
| 2022 | 12 | 3 | 15 |
| 2023 | 15 | 1 | 16 |
| 2024 | 7 | 4 | 11 |
| 2025 | 8 | 2 | 10 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biological Products" by people in Profiles.
-
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer Immunol Res. 2026 Aug 04; 14(8):1292-1306.
-
Biologics and Novel Therapeutics in Food Allergy. J Allergy Clin Immunol Pract. 2026 04; 14(4):762-770.
-
Real-World Effectiveness of Advanced Therapies in Microscopic Colitis. Clin Gastroenterol Hepatol. 2026 Aug; 24(8):2244-2254.
-
Insights from a Survey of Drug Formulation Experts: Challenges and Preferences in High-Concentration Subcutaneous Biologic Drug Development. AAPS J. 2025 09 11; 27(6):142.
-
Thermoreversibly assembled polymersomes for highly efficient loading, processing and delivery of protein and siRNA biologics. Nat Biomed Eng. 2026 Mar; 10(3):427-444.
-
Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025 06 01; 64(6):3434-3443.
-
Genome mining identifies a diversity of natural product biosynthetic capacity in human respiratory Corynebacterium strains. mSphere. 2025 Jun 25; 10(6):e0025825.
-
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025 May 15; 145(20):2303-2311.
-
Corticosteroid Use in Randomized Clinical Trials of Biologics and Small Molecules in Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2025 May 12; 31(5):1430-1440.
-
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun. 2025 May 06; 16(1):4205.